NCT03806751

A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: All
• Age: 19 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The overall aim of this project is to implement a non-invasive method of measuring quantitative regional cerebral blood flow (rCBF) on the UAB hybrid PET/MRI scanner to allow conducting such \[O-15\]water based scans with relative ease and safety in a large variety of important clinical and research applications. Participants will undergo imaging at baseline and after administration of a drug to increase cerebral blood flow to evaluate perfusion estimates during low and high flow states. The goal of this study is to generate data that will justify eliminating invasive arterial sampling in most \[O-15\]water-based PET protocols.

Conditions

• Validation of a New Noninvasive Method to Obtain the Arterial Input Function (AIF) Directly by PET Imaging

Interventions

Type	Name	Description
DRUG	[O-15]Water	All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
DRUG	Acetazolamide	The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.

Timeline

• Start date: 2025-02-01
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2019-01-16
• Last updated: 2024-03-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study